Roche Holding AG RHHBY
61.32 USD +1.95 (+3.28%)
At closeNov 9, 2026, 4:00 PM EST
60.49 Day range 61.74
43.11 52-week range 61.74
- YTD
- +18.91%
- 1 year
- +46.14%
- Market cap
- 390.86B
- EPS (ttm)
- 2.41
- P/E ratio
- 25.44
- YTD return
- +18.91%
- 1-year return
- +46.14%
- Volume
- 187.22K
- Avg volume
- 1.74M
- Open
- 60.70
- Previous close
- 59.37
- Day's range
- 60.49 – 61.74
- 52-week range
- 43.11 – 61.74
- Earnings date
- Feb 4, 2027
5D +0.82 (+1.36%)
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 1.49.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | 1.49 | — | — | — |
| Jul 23, 2026 | Jun 30, 2026 | 1.58 | 1.66 | +0.08 | +5.06% |
| Jan 29, 2026 | Dec 31, 2025 | 1.35 | 1.36 | +0.01 | +0.74% |
| Jul 24, 2025 | Jun 30, 2025 | 1.62 | 1.74 | +0.12 | +7.41% |
| Jan 30, 2025 | Dec 31, 2024 | 1.17 | 1.18 | +0.01 | +0.85% |
| Jul 22, 2024 | Jun 30, 2024 | 1.30 | 1.43 | +0.13 | +10.00% |
News
Zymeworks Enters Global License And Collaboration Agreement With Roche For Research, Development And Commercialization Of ZW209; Company Eligible For Upfront Payment Of $55M, With $40M Payment Upon Initiation Of Phase 1b Trial, And Additional Milestone Payments Of Up To $718M 
Swiss Pharma Giant Roche Suspends German Capital Commitments Amid Dispute Over Drug Discounts 
Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy
Your note
Sign in to keep a note on RHHBY — it syncs with the Stock Master app.